Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 146Head and Neck Neoplasms 80Squamous Cell Carcinoma of Head and Neck 69Rectal Neoplasms 46Colonic Neoplasms 42Carcinoma, Non-Small-Cell Lung 39Neoplasm Metastasis 35Neoplasms 25Carcinoma, Squamous Cell 20Pancreatic Neoplasms 17Lung Neoplasms 16Esophageal Neoplasms 15Stomach Neoplasms 12Recurrence 11Laryngeal Neoplasms 11Mouth Neoplasms 10Oropharyngeal Neoplasms 8Esophageal Squamous Cell Carcinoma 8Breast Neoplasms 8Adenocarcinoma Of Esophagus 8Tongue Neoplasms 7Uterine Cervical Neoplasms 6Nasopharyngeal Carcinoma 6Laryngeal Diseases 6Hypopharyngeal Neoplasms 6Colorectal Cancer Metastatic 6Carcinoma 6Adenocarcinoma of Lung 6Salivary Gland Neoplasms 5Cholangiocarcinoma 4

Interventions

Bevacizumab 2regorafenib 1Oxaliplatin 1IFL protocol 1FOLFOXIRI protocol 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Liver Metastasis Colon Cancer × Cetuximab × Clear all
NCT04832776 2021-04-06

FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases

Fudan University

Phase 2 Unknown
160 enrolled
Gastrointestinal

Liver Metastasis Colon Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡